Examples of Biologics Act in a sentence
In contrast, a biologic follow-on drug maker must meet the higher standards of biosimilarity or interchangeability.The pathway for rapid entry of generics is known as the Hatch- Waxman system;95 the biologic pathway is known by the more complex acronym, BPCIA (the Biologic Price Competition and Innovation Act, hereinafter the “Biologics Act”).96The Biologics Act provides greater protection for branded biologic drugs than Hatch-Waxman provides for branded non- biologic drugs.
In 2020, the agency did not list Somatuline Depot among the drugs that would be transitioned to Biologics Act regulation.
Pre-Litigation Patent-Related ProceduresThe Biologics Act attempts to streamline dispute resolution by placing specific procedures in place to guide the biosimilar applicant and reference product sponsor through the pre-litigation process.
Second, like the Drug Act, the Biologics Act also offers an abbreviated application process: when a company seeks to market a product that is “biosimilar” to or “interchangeable” with a product that has already been approved, it may submit an abbreviated biological license application(ABLA).
In other words, the Act required the FDA to, on March 23, 2020, transition substances that were approved as drugs, but now meet the current definition of “biological products,” to the Biologics Act.
Consistent with that mandate, on that date the FDA published a list of biological products that it deemed to be licensed under the Biologics Act, although they were initially approved under the Drug Act.
The Lead Party for each Collaboration Product will control all of the actions, filings, and communications with any follow-on biologic applicant under the Biologics Act with respect to such Collaboration Product, including generating the following documents: [***].
For companies using the Biologics Act, the FDA will play a key role in developing the regulations and policies that are critical to ensuring safe and efficacious biosimilar drugs.
Feldman & Misra, supra note 10, at 273 (“The challenges to biosimilars and thedisincentives in the Biologics Act are real.
We recommend output-based contracts as opposed to time-based contracts as observed with some Partners.